| Income statement (USD) | FY 2026 ended Jun 30, 2026 | FY 2025 ended Jun 30, 2025 | FY 2024 ended Jun 30, 2024 | FY 2023 ended Jun 30, 2023 | FY 2022 ended Jun 30, 2022 | FY 2021 ended Jun 30, 2021 |
|---|---|---|---|---|---|---|
| Research and development | 625.5K | 223.7K | 248.1K | 247.9K | 256.1K | 231.0K |
| Operating expenses | 18.19M | 57.28M | 1.54M | 1.78M | 1.99M | 1.81M |
| Operating income | -18.19M | -57.28M | -1.54M | -1.78M | -1.99M | -1.81M |
| EBITDA | -18.18M | -1.54M | -1.77M | -1.99M | -1.81M | |
| Interest expense | 430.5K | 563.8K | 665.8K | 532.8K | 568.8K | 449.5K |
| Income before tax | -18.86M | -58.92M | -1.95M | -2.79M | -2.71M | -2.14M |
| Income tax | -129.1K | -129.8K | -55.0K | -113.4K | ||
| Net income | -18.86M | -58.92M | -1.82M | -2.66M | -2.66M | -2.03M |
| EPS | -17.62 | -371.22 | -35,324.35 | -1.80 | -49.23 | -0.80 |
| EPS (diluted) | -17.62 | -371.22 | -35,324.35 | -1.80 | -49.23 | -0.80 |
| Diluted shares | 1.12M | 158.7K | 57 | 1.74M | 68.2K |
From Propanc Biopharma, Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.